2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Checkpoint Inhibitor, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Patient-Reported Outcomes, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2059 Proteasome haploinsufficiency creates therapeutic vulnerabilities in chromosome-deleted blood disorders

Haijiao Zhang, MD, Daniel Bottomly, MS2, Niveditha Nerlakanti, PhD3, Kangjin Jeong, PhD4, Xuan Luo, MD, PhD5, Basil Allen6, Thomas Koehnke, MD7, Jacob Porter, PhD8, Anastasiia Streltsova9, Isabel Kenna10, Emma Martin11, Shannon McWeeney, PhD12, Ravi Majeti, MD, PhD13, Andrew Emili, PhD14, Gordon Mills, MD, PhD15
1 Oregon Health Sciences University, Portland, Oregon, United States
2 Oregon Health Sciences University, Portland, Oregon, United States
3 Oregon Health Sciences University, Portland, Oregon, United States
4 Oregon Health Sciences University, Portland, Oregon, United States
5 Oregon Health Sciences University, Portland, Oregon, United States
6 Oregon Health Sciences University, Portland, Oregon, United States
7 Stanford University, Palo Alto, California, United States
8 Oregon Health Sciences University, Portland, Oregon, United States
9 Oregon Health Sciences University, Portland, Oregon, United States
10 Oregon Health Sciences University, Portland, Oregon, United States
11 Oregon Health Sciences University, Portland, Oregon, United States
12 Oregon Health Sciences University, Portland, Oregon, United States
13 Stanford University, Palo Alto, California, United States
14 Oregon Health Sciences University, Portland, Oregon, United States
15 Oregon Health Sciences University, Portland, Oregon, United States

Monosomy 7 is prevalent in myelodysplastic syndromes (MDS), leukemia, and bone marrow failure (BMF) disorders, where it is associated with ineffective hematopoiesis, leukemic progression, and poor prognosis. Despite its clinical significance, the disease pathogenesis and therapeutic vulnerability remain poorly understood. Several putative tumor suppressor genes on chromosome 7q have been implicated in affecting hematopoiesis, however, homozygous rather than hemizygous deletion of these genes is typically required to observe measurable phenotypes. Moreover, genes located outside the commonly deleted 7q region have received little attention. Haploinsufficiency occurs when having one copy of a gene results in reduced mRNA or protein expression that alters cellular function or generates specific vulnerabilities. Essential genes are genes required for cell viability and organismal survival, where complete loss results in lethality or severe functional defects. We hypothesize that there are haploinsufficient essential genes on chromosome 7, whose haploinsufficiency contributes to the pathogenesis and may also create therapeutic vulnerabilities in monosomy 7-associated blood disorders.

By integrating genomic, transcriptomic, proteomic, and functional dependency datasets with CRISPR-based validation, we first defined a group of chromosome 7 copy-number dosage-sensitive essential genes enriched in DNA replication and repair, cell-cycle regulation, metabolism, RNA processing, and proteostasis. Among these genes, PSMA2, located on chromosome 7p and encoding the α2 subunit of the 20S proteasome core particle, emerged as a critical dosage-sensitive determinant of cellular fitness. Using isogenic PSMA2-hemizygous deletion models and primary monosomy 7 leukemia specimens, we demonstrate that partial PSMA2 loss reduces PSMA2 expression, destabilizes multiple 20S core subunits, and impairs proteasome assembly and proteolytic activity. The resulting accumulation of ubiquitinated proteins and disruption of proteostasis create a selective dependency on residual proteasome capacity, rendering PSMA2-deficient cells preferentially sensitive to proteasome inhibition. Consistent with these findings, proteasome inhibitors produced marked antileukemic activity in primary monosomy 7 samples and significantly prolonged survival in leukemia cell line and primary monosomy 7 leukemia cell xenograft models.

Beyond its effects on proteostasis, PSMA2 haploinsufficiency caused coordinated post-transcriptional depletion of proteins required for DNA replication, replication-fork protection, and DNA repair, despite largely preserved transcription of the corresponding genes. These alterations impaired replication-fork progression, promoted nascent-fork degradation following hydroxyurea exposure, and increased replication-associated DNA damage, as evidenced by elevated γH2AX, phosphorylated RPA32, and increased comet tails. PSMA2-hemizygous deletion cells exhibited G2/M arrest and acquired selective sensitivity to genotoxic agents and DDR-targeting therapies, including Gemcitabine, ATR, and WEE1 inhibitors. Restoration of PSMA2 expression rescued proteasome and DDR protein abundance and reduced therapeutic sensitivity to these agents, establishing a direct causal relationship between PSMA2 dosage, proteasome integrity, and genome maintenance. Importantly, this principle extends beyond PSMA2: hemizygous loss of other 20S core subunit genes—including PSMA1, PSMA3–PSMA6, and PSMB2–PSMB6, but not PSMB1—similarly reduced proteasome abundance and increased sensitivity to proteasome inhibitors, identifying proteasome-subunit haploinsufficiency as a broader, therapeutically actionable class of copy-number alteration.

Together, our findings demonstrate that partial loss of a single dosage-sensitive proteasome core subunit is sufficient to destabilize the proteasome complex, disrupt both proteostasis and genome maintenance, and generate convergent vulnerabilities to proteasome inhibition, genotoxic therapy, and DDR-targeting agents. These results provide a mechanistic rationale for using proteasome-subunit deletions as biomarkers and for repurposing FDA-approved proteasome inhibitors—alone or in rational DDR-directed combinations—for patients with monosomy 7 or other cancers harboring hemizygous deletions of dosage-sensitive proteasome genes.

Haijiao Zhang, MD: turbine.ai - Consultancy (Includes expert testimony)